Table 2.
Summary of tumour responses by investigator assessment
| Parameter | Eribulin (n = 157) | Dacarbazine (n = 152) |
|---|---|---|
| Best overall response | ||
| CR, n (%) | 0 | 0 |
| PR, n (%) | 8 (5) | 11 (7) |
| SD, n (%) | 73 (47) | 75 (49) |
| PD, n (%) | 69 (44) | 56 (37) |
| Not evaluable, n (%) | 2 (1) | 1 (1) |
| Unknown, n (%) | 5 (3) | 9 (6) |
| Objective response rate | ||
| ORR (95% CI) | 5 (2, 10) | 7 (4, 13) |
| Disease control rate | ||
| DCR (95% CI) | 52 (44, 60) | 57 (48, 64) |
| Durable stable disease rate | ||
| dSD (95% CI) | 36 (28, 44) | 45 (37, 54) |
CI confidence interval, CR complete response, DCR disease control rate (defined as proportion of PR+CR+SD), dSD durable stable disease (defined as the proportion with stable disease for ≥11 weeks), HR hazard ratio, ORR objective response rate (defined as the proportion of CR + PR), PFS progression-free survival, PD progressive disease, PR partial response, SD stable disease